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Introduction: Previous in vitro and in vivo studies demonstrate protective properties of kissorphin (KSO) 
peptides against amyloid-β (Aβ) neurotoxicity1,2. Overexpression of the KiSS-1 gene, that encodes the KSO 
peptides, is also neuroprotective
1,3. Endocannabinoids and KSO peptides are neuroprotective against Aβ 25-35, 
but not Aβ 31-35 peptides1,4. The KiSS-1 gene expression is regulated by endocannabinoids 5. The aim of this 
study was to determine whether endocannabinoids contribute to KSO protection against Aβ toxicity using a 
CB1 cannabinoid receptor antagonist. 
Method: This study employed MTT cell viability assays to investigate the effects of the CB1 antagonist AM281 
on KSO 1-6 protection against Aβ 25-35 neurotoxicity in human neuroblastoma SH-SY5Y cells. The effects of 
AM281 on Aβ 25-35 induced neurotoxicity in KiSS-1 gene overexpressing SH-SY5Y cells (PKiSS)1,3 was also 
investigated
1,3
. Data was analyzed by one-way analysis of variance (ANOVA). 
Results: The CB1 antagonist AM281 (0.01-10µM) promoted a concentration dependent increase in 10µM Aβ 
25-35 induced neurotoxicity in SH-SY5Y cells in the presence of 10µM KSO 1-6 (Figure 1A). The PKiSS 
protection against 10µM Aβ 25-35 was reversed by the CB1 antagonist AM281 (10µM) and anti-KSO antibody 
(1µg/ml). In the presence of anti-KSO antibody 10µM 2-AG was protective against 10µM Aβ 25-35. 
 
Figure 1. (A) Dose-response curves for AM281 in the presence of 10µM Aβ 25-35 with or without 10µM KSO 
1-6, on MTT reduction in SH-SY5Y cells. (B) PKiSS SH-SY5Y cells were exposed to 10µM Aβ 25-35 alone; 
10µM Aβ 25-35 plus 10µM AM281; 10µM Aβ 25-35 plus 1µg/ml anti-KSO antibody; 10µM Aβ 25-35 plus 
1µg/ml control antibody; 10µM Aβ 25-35 plus 1µg/ml anti-KSO antibody with 10µM 2-AG; 10µM Aβ 25-35 
plus 1µg/ml control antibody with 10µM 2-AG; and cell viability determined by MTT reduction. Results are 
mean ± SEM (n=8 for each data point); * = P< 0.05 vs Aβ 25-35 alone (one-way ANOVA). 
Conclusion: In conclusion, protection against Aβ 25-35 induced neurotoxicity by KSO and KiSS-1 
overexpression in SH-SY5Y cells is reversed by the AM281 CB1 antagonist. Anti-KSO antibodies prevent 
neuroprotection by KiSS-1 overexpression and 2-AG restores neuroprotection. This suggests KSO 
neuroprotection against Aβ involves activation of endocannabinoids. 
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